- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-RM35/ MRPL35/ L35mt functional antibody
Anti-RM35/ MRPL35/ L35mt functional antibody for cell culture, ELISA & in-vivo assay
Go to MRPL35/MRPL35 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-SE1497-Ab-1/ GM-Tg-hg-SE1497-Ab-2 | Anti-Human MRPL35 monoclonal antibody | Human |
| GM-Tg-rg-SE1497-Ab-1/ GM-Tg-rg-SE1497-Ab-2 | Anti-Rat MRPL35 monoclonal antibody | Rat |
| GM-Tg-mg-SE1497-Ab-1/ GM-Tg-mg-SE1497-Ab-2 | Anti-Mouse MRPL35 monoclonal antibody | Mouse |
| GM-Tg-cynog-SE1497-Ab-1/ GM-Tg-cynog-SE1497-Ab-2 | Anti-Cynomolgus/ Rhesus macaque MRPL35 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-SE1497-Ab-1/ GM-Tg-felg-SE1497-Ab-2 | Anti-Feline MRPL35 monoclonal antibody | Feline |
| GM-Tg-cang-SE1497-Ab-1/ GM-Tg-cang-SE1497-Ab-2 | Anti-Canine MRPL35 monoclonal antibody | Canine |
| GM-Tg-bovg-SE1497-Ab-1/ GM-Tg-bovg-SE1497-Ab-2 | Anti-Bovine MRPL35 monoclonal antibody | Bovine |
| GM-Tg-equg-SE1497-Ab-1/ GM-Tg-equg-SE1497-Ab-2 | Anti-Equine MRPL35 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-SE1497-Ab-1/ GM-Tg-hg-SE1497-Ab-2; GM-Tg-rg-SE1497-Ab-1/ GM-Tg-rg-SE1497-Ab-2; GM-Tg-mg-SE1497-Ab-1/ GM-Tg-mg-SE1497-Ab-2; GM-Tg-cynog-SE1497-Ab-1/ GM-Tg-cynog-SE1497-Ab-2; GM-Tg-felg-SE1497-Ab-1/ GM-Tg-felg-SE1497-Ab-2; GM-Tg-cang-SE1497-Ab-1/ GM-Tg-cang-SE1497-Ab-2; GM-Tg-bovg-SE1497-Ab-1/ GM-Tg-bovg-SE1497-Ab-2; GM-Tg-equg-SE1497-Ab-1/ GM-Tg-equg-SE1497-Ab-2 |
| Products Name | Anti-MRPL35 monoclonal antibody |
| Format | mab |
| Target Name | MRPL35 |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category of antibody | FACS/Biofunctional Antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-MRPL35 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-SE1497-Ag-1 | Recombinant multi-species RM35/ MRPL35/ L35mt protein |
| ORF Viral Vector | pGMLP004733 | human MRPL35 Lentivirus plasmid |
| ORF Viral Vector | vGMLP004733 | human MRPL35 Lentivirus particle |
| ORF Viral Vector | pGMLPm004211 | mouse Mrpl35 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm004211 | mouse Mrpl35 Lentivirus particle |
Target information
| Target ID | GM-SE1497 |
| Target Name | MRPL35 |
| Gene ID | 51318,66223,297334,717628,612007,101088072,540278,100053006 |
| Gene Symbol and Synonyms | 1110066C01Rik,L35mt,MRP-L35,MRPL35 |
| Uniprot Accession | Q9NZE8,Q3SZA9 |
| Uniprot Entry Name | RM35_HUMAN,RM35_BOVIN |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000132313 |
| Target Classification | N/A |
The target: MRPL35, gene name: MRPL35, also named as L35mt, MRP-L35. Mammalian mitochondrial ribosomal proteins are encoded by nuclear genes and help in protein synthesis within the mitochondrion. Mitochondrial ribosomes (mitoribosomes) consist of a small 28S subunit and a large 39S subunit. They have an estimated 75% protein to rRNA composition compared to prokaryotic ribosomes, where this ratio is reversed. Another difference between mammalian mitoribosomes and prokaryotic ribosomes is that the latter contain a 5S rRNA. Among different species, the proteins comprising the mitoribosome differ greatly in sequence, and sometimes in biochemical properties, which prevents easy recognition by sequence homology. This gene encodes a 39S subunit protein. Sequence analysis identified three transcript variants. Pseudogenes corresponding to this gene are found on chromosomes 6p, 10q, and Xp. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
